ADA-friendly PDF: Consensus Statements Regarding the use of Sacituzumab Govitecan in Patients with Metastatic, Hormone Receptor-Positive, HER2- Negative Breast Cancer

Treatment Guidelines: Sacituzumab Govitecan for Metastatic, HR-Positive, HER2-Negative Breast Cancer

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on April 5, 2023 to discuss recommendations for the for the use of sacituzumab govitecan in patients with metastatic, HR-positive, HER2-negative breast cancer.